TON - November 2012, Vol 5, No 10

TON - November 2012, Vol 5, No 10 published on November 21, 2012 in Rare Cancers
Interest in pancreatic neuroendocrine tumors (pNETs) has grown since the recent approval of targeted agents for advanced disease, as was evident by the attendance at several sessions during the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.1
TON - November 2012, Vol 5, No 10 published on November 21, 2012 in Noteworthy Numbers
In 2012, approximately 1.6 million new cases of cancer will be diagnosed in the United States.1 A family caregiver, or informal caregiver, will become a necessity for many of the newly diagnosed patients. A family caregiver provides emotional, physical, psychological, and spiritual support to the patient. This, in turn, can take a toll on a caregiver’s own physical, emotional, and even financial health as well. The following statistics provide a glimpse into the characteristics of these unique care providers.
TON - November 2012, Vol 5, No 10 published on November 21, 2012 in Breast Cancer
According to a study from the US Oncology Network, breast cancer patients treated with adjuvant chemotherapy have no increased risk for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), at least within the first 3 years of treatment. The study was presented at the American Society of Clinical Oncology 2012 Breast Cancer Symposium by Neelima Denduluri, MD, of Virginia Cancer Specialists.1
The mission of the John Theurer Cancer Center is to deliver extraordinary care that is multidisciplinary, personalized, innovative, and at the appropriate cost with superior outcomes to the most satisfied patients.
Oncology experts from all over the globe arrived in Vienna, Austria, to attend the Euro­pean Society for Medical Oncology (ESMO) 2012 Congress. Attendance broke all records, with 16,394 delegates, many of them from outside of Europe: 1116 from the United States, 539 from Japan, 479 from China, 292 from Argentina, and 258 from Brazil.
TON - November 2012, Vol 5, No 10 published on November 15, 2012 in Lung Cancer
In a phase 3 head-to-head comparison trial, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib proved more effective than standard chemo­therapy with pemetrexed or docetaxel as a second-line treatment for non–small cell lung cancer (NSCLC) patients with the ALK genetic abnormality.
TON - November 2012, Vol 5, No 10 published on November 15, 2012 in Breast Cancer
Early breast cancer patients who gain weight after treatment are at increased risk for breast cancer recurrence, according to an Italian study presented at the European Society for Medical Oncology 2012 Congress, held in Vienna, Austria.
TON - November 2012, Vol 5, No 10 published on November 15, 2012 in From the Editors
In this month’s issue of The Oncology Nurse-APN/PA (TON), we bring you the news from the European Society for Medical Oncology 2012 Con­gress. Some of the most exciting news came from the update of the PROFILE 1007 trial, with results showing that crizotinib was more effective than standard chemo­therapy with pemetrexed or doce­taxel as a second-line treatment for non–small cell lung cancer. We also cover the latest treatment information about pancreatic neuroendocrine tumors, which, as one presenter noted, is “not a rare disease any longer.”
TON - November 2012, Vol 5, No 10 published on November 15, 2012 in FDA News & Updates
The US Food and Drug Administration (FDA) has approved omacetaxine mepesuccinate subcutaneous injection (Synribo, Teva Pharmaceutical Industries) for the treatment of adult patients with chronic myeloid leukemia (CML) with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors (TKIs).
Single-agent doxorubicin remains the standard of care as first-line treatment for unresectable or metastatic soft tissue sarcomas, according to results of a phase 3 trial conducted by EORTC and presented at the Presidential Symposium during the ESMO 2012 Congress (Abstract LBA7).
Page 1 of 2
Results 1 - 10 of 16